Search for a trial

A 64-week, two-arm, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular agerelated macular degeneration (TALON)

To evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control (TtC) regimen for the treatment of patients with neovascular age-related macular degeneration (nAMD) with the objective to evaluate the potential to reduce treatment…

Visual impairment in children with a brain tumor in the Netherlands: a prospective nationwide study using standard visual testing and optical coherence tomography

Primary objective:To study whether changes in OCT parameters lead to earlier detection of visual decline compared to standard ophthalmological testing (visual field, visual acuity) in children with a brain tumor. Secondary objective: To study the…

A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

To evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD).

Reducing fatigue in visually impaired adults with E-nergEYEze: An RCT to assess the cost-effectiveness of a blended vision-specific E-health based cognitive behavioral & self-management intervention.

The objective of the study is to develop and test a blended vision-specific E-health-based cognitive behavioral & self-management intervention (*E-nergEYEze*). Our specific goals are: (1) to further develop E-nergEYEze for visually impaired…

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)

To evaluate the efficacy and safety of brolucizumab in the treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) and its potential to reduce the treatment burden for patients.